The FDA label update boosts GE HealthCare’s Vizamyl to a market advantage despite the emergence of blood-based tests.

Small study hints anti-amyloid therapy may keep Alzheimer’s symptoms at bay in certain patients By Brenda Goodman , CNN 11 minute read ...

GE HealthCare (GEHC) announced that the U.S. Food and Drug Administration has approved an updated label for its positron emission tomography or PET imaging agent Vizamyl (flutemetamol F 18 injection) ...

The revised label expands the brain-scan agent's use, and means that Vizamyl can now be used to diagnose Alzheimer's and predict the development of dementia due to disease, the company said. The ...

Moving Beyond Anti-amyloid Therapy for the Prevention and Treatment of Alzheimer's Disease. Michael A Castello; John David Jeppson; Salvador Soriano. Disclosures. BMC Neurol. 2014;14(169) ...

However, in both cases, NICE immediately published draft guidance that concluded the anti-amyloid drugs were too expensive to ...

Voyager Therapeutics presents data on tau silencing therapy VY1706 and anti-amyloid therapy at ASGCT 2025. Quiver AI Summary. Voyager Therapeutics, Inc. has announced that it will present eight ...

Tiziana (TLSA) is showing groundbreaking advancements in Alzheimer's & MS treatments with foralumab. Key trials & market ...

An FDA-approved anti-amyloid infusion therapy, lecanemab (Leqembi, Eisai) is prescribed for those in the early stages of symptomatic Alzheimer’s disease. However, ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that gantenerumab, an anti-amyloid beta antibody developed for subcutane ...